Form 4: Protalix BioTherapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Aharon Schwartz, a Director of Protalix BioTherapeutics, Inc., reported multiple transactions in common stock on September 3, 2026.
Summary
- Grant/award: acquired 17,000 Stock Options (Right to Buy) on September 3, 2026; holds 17,000 after (Direct).
- Grant/award: acquired 8,500 Restricted Stock Units on September 3, 2026; holds 8,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Aharon Schwartz — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Grant/award | Stock Options (Right to Buy) | 17,000 | — | — | 17,000 |
| 2026-09-03 | Grant/award | Restricted Stock Units | 8,500 | — | — | 8,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Grant/award (17,000 shares) |
| 2026-09-03 | Grant/award (8,500 shares) |
Keywords
insider transaction, Form 4, PLX, Protalix BioTherapeutics, Inc., neutral, Aharon Schwartz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.